Edition:
United Kingdom

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

4.29USD
23 May 2018
Change (% chg)

$0.33 (+8.33%)
Prev Close
$3.96
Open
$3.99
Day's High
$4.30
Day's Low
$3.98
Volume
302,042
Avg. Vol
161,169
52-wk High
$4.30
52-wk Low
$0.94

Chart for

About

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $80.42
Shares Outstanding(Mil.): 71.17
Dividend: --
Yield (%): --

Financials

  ARQL.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.39 -- --
ROI: -91.39 1.57 14.38
ROE: -120.33 2.43 16.07

BRIEF-Arqule Reports Q1 Loss Per Share Of $0.07

* Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S

07 May 2018

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

17 Apr 2018

BRIEF-ArQule Reports Q4 Loss Per Share $0.09

* ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

05 Mar 2018

BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China

* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA

07 Feb 2018

BRIEF-ArQule Files For Offering Of Up To 17.1 Million Shares

* ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: (http://bit.ly/2ivqMQn) Further company coverage:

06 Dec 2017

Earnings vs. Estimates